Kisqali coated tablets 200mg №63

Use Kiskali is indicated for the treatment of postmenopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with an aromatase inhibitor as first-line endocrine therapy. How to take Information on Kiskali dosages is available in the instructions for use. In a phase III clinical study, 568 patients received Kiskali at the recommended dose of 600 mg according to a treatment regimen (days 1-21 of a 28-day cycle). Contraindications Kiskali is contraindicated during pregnancy and breastfeeding. It is also contraindicated for children. Use with caution in case of impaired renal and hepatic function. Storage Information on Kiskali storage conditions is available in the product description.